Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Summary Prescient Therapeutics (ASX:PTX): We spoke with Steve Yatomi-Clarke, CEO of Prescient Therapeutics, about the exciting new...
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...
(ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its...
Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting...
Biotech company Prescient Therapeutics has given investors a glimpse into the progress of it’s next-generation...
In an announcement made this morning, the Melbourne-based company revealed its OmniCAR platform continues to...
Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell &...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.